Healthy endothelium plays a central role in cardiovascular control. Therefore, endothelial dysfunction (ED), which is characterized by an imbalance between relaxing and contracting factors, procoagulant and anticoagulant substances, and between proinflammatory and antiinflammatory mediators, may play a particularly significant role in the pathogenesis of atherosclerosis. Endothelial dysfunction is closely related to different risk factors of atherosclerosis, and to their intensity and duration. The involvement of risk factors in ED is also
supported by results of interventions studies that showed regression of ED with treatment of risk factors. Because risk factors are commonly accompanied by decreased bioavailability of nitric oxide, the common denominator whereby different risk factors cause ED is most probably increased oxidative stress. Endothelial dysfunction may promote atherogenesis through different mechanisms such as increased adherence of monocytes, macrophages, and enhanced permeability of the endothelial layer. Further, ED probably plays an important role in the growth of atherosclerotic lesions and in the development of thrombotic complications in late stages of the disease. Because ED is a key underlying factor in the atherosclerotic process, markers of endothelial abnormalities have been sought. Detection of ED is based on tests of endothelium-dependent vasomotion (dilation capability of peripheral and coronary arteries) and on circulating markers of endothelial function (endothelin-1, von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and adhesion molecules). Using these tests it is possible to follow the dose response of harmful effects of risk factors, and the effects of preventive procedures on vessel wall function. Key Words: Endothelial function&mdash;Atherosclerosis&mdash;Vasodilation&mdash;Markers of endothelial damage.
The vascular endothelium is an important regulatory organ in maintaining of cardiovascular homeostasis. Normal endothelial function includes control over thrombosis and thrombolysis, platelets and leukocyte interaction with the vessel wall, and regulation of vascular tone and smooth muscle cell proliferation. One of the most important regulatory and vasoactive substances produced by endothelial cells is nitric oxide ~~It~). Nitric oxide modulates vascular tone, and inhibits the interaction between blood cells and the vessel wall. In addition, NO appears to be an endogenous inhibitor of tumor necrosis factor and the expression of proinflamll1atory molecules, such as the vascular cell adhesion molecule (VCAM-1) and the chemoattractant protein-1 '(1); Because healthy endothelium plays a central role in cardiovascular control, it follows that endothelial damage may contribute to disease states characterized by vasoconstfiction, inflammation, excessive thrombus formation, leukocyte adhesion to vessel walls, hypertension, and atherosclerosis ~~;3~~.
ENDOTHELIAL DYSFUNCTION
Endothelial dysfunction is characterized by an imbalance between relaxing and contracting factors, between anticoagulant and procoagulant mediators, or between growth-inhibiting and promoting factors. Such dysfunction can result from mechanical or biochemical injury to the endothelium,. Physical damage of the endothelium is mostly caused by hypertension; several other risk factors like hypercholesterolemia, diabetes, and smoking probably cause injury to the endothelium through biochemical mechanisms. Therefore, vessel wall damage may results in endothelial dysfunction and can be clinically manifested as thrombosis or atherosclerosis (4).
INVOLVEMENT OF ENDOTHELIAL DYSFUNCTION IN ATHEROGENESIS
Endothelial dysfunction has been demonstrated in subjects with different risk factors of atherosclerosis, such as hypercholesterolemia (5) , diabetes (6,7), hypertension (8) , smoking (9) , and in patients with atherosclerotic disease (~c~rnnary, peripheral arterial) (3, 10) . We demonstrated that endothelial dysfunction progresses with the duration of hypertension, diabetes, or smoking and that a close relationship exists between the intensity of an individual risk factor or the number of presented risk factors and endothelial function (7,8,1 1). Furthermore, treatment of risk factors resets in improvement of endothelial dysfunction. It has been shown that treatment of hypercholesterolemia with different statins improves endothelial function (12, 13) . Regression of endothelial dysfunction was observed during treatment of arterial hypertension with various drugs (14) and during physical training of patients with cardiac insufficiency and polymetabolic syndrome (15) . We also observed improvement of endothelial dysfunction duping growth hormone replacement in growth hormone-deficient patients (16) . Therefore, a dose-response relation exists between risk factors of atherosclerosis and endothelial dysfunction.
The mechanisms whereby risk factors cause endothelial dysfunction are largely unknown; a common denominator for all these conditions is probably increased oxidative stress, which has therefore been suggested as an important cause of endothelial dysfunction. Most known risk factors cause excessive production of superoxide anions, with consequent degradation of NO before it can reach target tissues (17) . Decreased bioavailability of NO in the presence of risk factors is most probably also caused by decreased expression of nitrogen oxide synthase activity. Because NO acts as a vasodilator and inhibits platelet adherence and aggregation, smooth muscle proliferation, and endothelial cell-leukocyte interaction, decreased NO activity may contribute importantly to the initiation and progression of atherosclerotic lesions (2) . The consequences of mechanical or chemical damage of the endothelium by different risk factors are also several cellular processes, such as inflammation and lipoprotein oxidation, that maintain endothelial dysfunction and promote atherosclerosis. Endothelial dysfunction is most probably a consequence of the harmful effects of risk factors of atherosclerosis on the wall. However, recent observations favor the hypothesis that endothelial dysfunction could also be a primary, directly inherited defect. Thus, some observations showed that dysfunctional endothelial , NO synthase gene polymorphism is associated with some risk factors (e, g., hypertension) and is therefore not a consequence, but a primary abnormality (18) .
. This assumption is also supported by the demonstration of endothelial dysfunction in normotensive siblings ! of parents with essential hypertension in one of our ' studies (8) . ' Endothelial dysfunction probably promotes atherogen-: esis through different mechanisms, such as increased adherence of monocytes and enhanced permeability of the . endothelial layer to monocytes/macrophages and lipo-. proteins, which then accumulate in the vessel wall. It was indicated that endothelial dysfunction is also related to increased platelet adherence and smooth muscle cell migration and proliferation, both of which are involved in atherogenesis. Because one of the earliest events in atherogenesis is the adherence of circulating monocytes to intact endothelial cells, in some cases atherosclerosis behaves as a chronic inflammatory process. However, this presumption does not preclude. involvement of endothelial dysfunction, which most probably initiates different pathologic processes, including inflammation,.
Furthermore, is has been shown that endothelial dysfunction that precedes the early morphologic atherosclerotic changes in the arterial wall plays an important role in the development and growth of atherosclerotic lesions, and in the development of ischemia and thrombosis in the late stages of the disease (19) .
Because the endothelial vasodilator function of the microvessels is an important determinant of tissue perfusion, microvascular endothelial dysfunction may play a particularly significant role in the pathogenesis of tissue ischemia. In advanced atherosclerosis, endothelial dysfunction in the coronary arteries, especially during periods of increased demand, may be manifested clinically as periodic episodes of myocardial ischemia (20) .
INDICATORS OF ENDOTHELIAL DYSFUNCTION
After the recognition that atherosclerosis develops over decades and therefore has a long pr~clinical (silent) phase before the onset of clinical symptoms, and that in this early phase changes of the arterial wall are mostly reversible and preventable, there has been considerable interest in developing diagnostic tools for detecting and monitoring early vascular changes in asymptomatic subjects. Because endothelial dysfunction is a key underlying factor in the atherosclerotic process, markers of endothelial abnormalities have been sought, particularly those involving disturbed endothelium-dependent vasomotion or related cellular products (21) . Because endothelium has different functions, different tests would be needed to measure several different aspects of endothelial dysfunction. Areas of potential interest for detection of endothelial dysfunction include circulating markers of endothelial function and tests of endotheliumdependent vasomotion. Moreover, circulating adhesion molecules may serve as markers of endothelial damage or atherosclerosis.
Circulating markers of endothelial function
Endothelial injury may result in the release of various factors that can be detected in the circulation and can be ' potentially used as markers of endothelial dysfunction.
Endothelin-I
Endothelin-1-is an endothelium-derived peptide that has powerful vasoconstrictor properties. Increased levels of endothelin-l have been demonstrated in conditions associated with endothelial dysfunction, such as atherosclerosis, hypercholesterolemia, and cigarette smoking (28, 29) . Furthermore, oxidized low-density lipoproteins has been shown to stimulate endothelin-1 production and secretion (30) . injury to vascular endc~theli~l c~ll~ prc~bably triggers the release of endothelin-1, and therefore it has been suggested that the levels of circulating endothelin in plasma may represent a marker of endothelial dysfunction. Because en~c~chelin-also has mitogenic properties, it may also play a role in the development of premature atherosclerosis.
'~c~ft ~~il~~~r~rr~~~~'crc~tot°T he von Willebrand factor (vWF) is a glycoprotein synthesized mainly by vascular endothelial cells. It has important functions in hemostasis, participating in the coagulation and in the formation of platelet plugs at sites of endothelial damage. von Willebrand factor is elevated in patients with hypercholesterolemia, and reduction of total cholesterol has been shown to be associated with a reduction in vWF levels (31) . Its levels are elevated in situation. characterized by vascular damage with denudation of the endothelium, and it has been suggested that injured endothelial cells leak vWF, leading to increased plasma levels. Recent studies have shown that elevated levels of vWF may be predictive of recurrent cardiovascular events in patients with known cardiovascular disease (32) . Tissccc ~~lr~.srnir~r~~~~n activator crnd ~~fca.sxn~tir~~c~~,~t i~c~tr~~~ inhibitors-I Tissue plasminogen activator is a protein released by endothelial cells. It activates the reaction in which plasminogen is converted to plasmin. Tissue plasminogen activator regulates the fibrinolytic activity of blood in balance with plasminogen activator inhibitor,-1, another product of endothelial cells, serving as the primary inhibitor of tissue plasminogen activator. These circulating vascular endothelial markers are elevated in hypercholesterolemia (33) . Furthermore, prospective studies have shown that high concentrations of tissue plasminogen activator antigen in healthy men may be associated with a subsequent risk of myocardial infarction (34) and stroke (35) . Data from the Atherosclerosis Risk m Com-(ARIC) study have shown that increased levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are associated with subclinical carotid atherosclerosis, measured as increased intima-media thickness (36) . Therefore, the different proteins involved in hemostasis and synthesized by endothelial cells have been proposed as markers of endothelial dysfunction. The main problem is the relatively poor specificity of these markers, which may hamper their use in detection or monitoring of endothelial dysfunction. Functional methods for studying endothelial function
NO-dependent vasodilation
Most of the functional methods for in vivo endothelial testing examine the ability of the endothelium to cause vasodilation in response to the pharmacologic and physiologic stimuli that increase the endothelial release off NO.
In vivo assessment of coronary endothelial function in humans was first reported by Ludmer et al. in 1986 (22) . The coronary artery diameter was measured by quantitative angiography before and after intracoronary infusion of acetylcholine. The dilation capability of the coronary arteries was assessed using Doppler wires or catheters. Later, these techniques provided valuable insights into the risk factors of endothelial dysfunction in coronary arteries and into the role of endothelial dysfunction in preceding overt atherosclerosis (23) . The potential four reversibility of endothelial dysfunction in the coronary arteries by therapeutic intervention has also been assessed by this methodology ( l ~). The major disadvantage of intr~.-art~rial tests is their invasive nature, which makes them generally unsuitable for routine use in subjects who are at risk for atherosclerosis but who have no clinical symptoms or signs of disease. Therefore, noninvasive or minimally invasive clinical tests of endothelial function have been developed.
Positron emission tomography is a unique method that enables noninvasive quantitation of myocardial blood flow, which is dependent on the endothelial function of macrovessels and microvessels. By measuring blood flow at rest and after pharmacologic stimulation with dipyridamole or adenosine, it is possible to calculate the coronary blood flow reserve. In cases with impairment in coronary reactivity, the blood flow reserve is decreased and may represent an early marker of endothelial dysfunction and subclinical coronary atherosclerosis (24, 25) . Ẽ ndothelial function may also be tested noninvasivcly ! in the peripheral conduit arteries using high-r~sc~lution ' 1 external vascular ultrasonography. In this noninvasive f method, arterial diameter is measured in response to an increase in shear stress, which causes endothelium-j dependent dilatation, and an endothelium-independent ) dilatation in response to sublingual nitroglycerin. The ! brachial arterial dilator response to increased blood flow I during reactive hyperemia has been shown to be mainly caused by endothelial release of NO (26) , and to corre-3 late significantly with coronary endothelial function / and with the extent and severity of coronary athero-! sclerosis ~2~). ' Ñ oninvasive ultrasonography has been applied widely ! i to asymptomatic subject groups. These studies have provided information on the effects of various risk factors on ; early ~.tla:~rc~;~enesis; Because these techniques are a~eu-; ! rate and relatively reproducible, serial studies may be j performed including trials of reversibility of endothelial dysfunction in asymptomatic subjects at high risk of arj trial atherosclerotic disease. ' ! Adhesion molecules .. B inding of circulating leukocytes to the vascular endothelium and further leukocyte migration into'the sub-; endothelial space are major processes in the development i of atherosclerosis. These events are mediated through ! diverse cellular adhesion molecules that are expressed on ! the surface of vascular endothelial cells such as vascular j cell adhesion molecules-1 I (VCAM-1), endothelial-! leukocyte adhesion molecule (E-selectin and P-selectin), and intercellular adhesion molecule-(I~AM-l~. Circu-! lating soluble forms of these adhesion molecules have ! been detected in plasma. The origin and function of these i circulating soluble adhesion molecules are unclear, but j they most likely arise from endothelial cells (37) . ! Several studies have suggested that circulating adhe-' sion molecules may serve as markers of endothelial dam-! age or atherosclerosis. The ARIC study showed that El selectin and ICAM-1 are associated with carotid artery j intima-media thickness and are independent predictors of j incident coronary artery disease (36) . This study also ! showed higher levels of ICAM-in smokers. Squadrito ! et al. (38) observed higher levels of circulating I~AI~I-I' I ! and E-selectin in patients with acute myocardial infarc-' tion. Increased levels of plasma P-selectin have been j observed in cases of unstable angina (39) , myocardial ! infarction (40) , and hypercholesterolemia (41) . Elevated ) levels of ICAM-were also found in patients with pet ripheral vascular disease (42) . Furthermore, ICAM-1 ! levels may predict cardiovascular event rates in appar-! ently healthy men (43) .
! Of the risk factors, serum lipoproteins seem to be es-! pecially related to the levels of circulation adhesion mol-! ecules. In the study by Hackman et al. (44) , dyslipidemia ! was associated with elevated levels of ICAM-1, VCAM-! 1, and E-selectin. Successful therapy with lipid-lowering statins significantly reduced the levels of circulating Eselectin. Therefore, these studies suggested that cell adhesion molecules may serve as possible markers of the / , efficacy of lipid-lowering therapy. j
